Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
XON Intrexon Corporation daily Stock Chart
XON [NASD]
Intrexon Corporation
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-3.68 Insider Own0.30% Shs Outstand155.88M Perf Week-9.15%
Market Cap819.93M Forward P/E- EPS next Y-0.90 Insider Trans- Shs Float136.87M Perf Month-16.11%
Income-497.30M PEG- EPS next Q-0.24 Inst Own75.00% Short Float25.65% Perf Quarter-29.40%
Sales135.00M P/S6.07 EPS this Y70.50% Inst Trans0.17% Short Ratio32.70 Perf Half Y27.98%
Book/sh1.82 P/B2.89 EPS next Y22.40% ROA-65.00% Target Price10.00 Perf Year-65.28%
Cash/sh0.81 P/C6.52 EPS next 5Y42.50% ROE-133.10% 52W Range3.95 - 15.35 Perf YTD-19.57%
Dividend- P/FCF- EPS past 5Y-22.90% ROI-84.20% 52W High-65.73% Beta2.28
Dividend %- Quick Ratio3.20 Sales past 5Y46.50% Gross Margin53.90% 52W Low33.16% ATR0.39
Employees882 Current Ratio3.50 Sales Q/Q-20.50% Oper. Margin- RSI (14)36.38 Volatility6.31% 6.42%
OptionableYes Debt/Eq0.92 EPS Q/Q50.10% Profit Margin- Rel Volume1.21 Prev Close5.61
ShortableYes LT Debt/Eq0.90 EarningsNov 07 AMC Payout- Avg Volume1.07M Price5.26
Recom3.00 SMA20-9.94% SMA50-14.41% SMA200-17.00% Volume1,296,252 Change-6.16%
Mar-01-19Downgrade Northland Capital Outperform → Market Perform
Jul-17-18Resumed Stifel Buy $72
Jul-16-18Downgrade BofA/Merrill Neutral → Underperform
Nov-10-17Reiterated Stifel Buy $57 → $39
Nov-10-17Reiterated Stifel Buy $39 → $57
Dec-29-16Initiated Northland Capital Outperform $40
May-03-16Initiated JMP Securities Mkt Outperform
Mar-01-16Reiterated Stifel Buy $69 → $57
Mar-01-16Reiterated Mizuho Neutral $28 → $29
Jan-25-16Reiterated Mizuho Neutral $42 → $28
Nov-11-15Upgrade Mizuho Underperform → Neutral $45 → $42
Oct-19-15Reiterated Wunderlich Buy $70 → $50
Oct-14-15Initiated BofA/Merrill Neutral $35
Sep-21-15Initiated Stifel Buy $69
Aug-11-15Downgrade Mizuho Neutral → Underperform $45
Aug-11-15Downgrade JP Morgan Overweight → Neutral
Jul-27-15Reiterated Wunderlich Buy $55 → $70
Jun-09-15Initiated Wunderlich Buy $55
Mar-10-15Downgrade Mizuho Buy → Neutral $14
Mar-03-15Reiterated Mizuho Buy $32 → $50
Oct-03-19 06:06AM  Have Insiders Been Selling Intrexon Corporation (NASDAQ:XON) Shares This Year? Simply Wall St.
Sep-26-19 07:30AM  David H. Witte to lead MBP Titan LLC PR Newswire
Sep-24-19 04:00AM  Next Green Wave Achieves Operational Milestones For Intrexons Botticelli Cannabis Plantlet Production GlobeNewswire
Aug-29-19 09:01AM  Teladoc Gains on Growing Acceptance for TeleHealth Services Zacks
Aug-19-19 07:30AM  ActoBio Therapeutics Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten PR Newswire
05:59AM  Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77% Simply Wall St.
Aug-15-19 08:45PM  Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT Thomson Reuters StreetEvents
Aug-12-19 03:21AM  Intrexon Corp (XON) Q2 2019 Earnings Call Transcript Motley Fool
Aug-09-19 10:59AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2 Zacks -8.79%
Aug-08-19 05:15PM  Intrexon Reports Second Quarter and First Half 2019 Financial Results PR Newswire
Aug-05-19 07:30AM  Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PR Newswire -7.39%
Aug-01-19 10:33AM  Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline Zacks
07:30AM  Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th PR Newswire
Jul-09-19 04:44PM  Here's Why Intrexon Jumped 58% in June Motley Fool
Jul-05-19 07:18AM  What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It? Simply Wall St.
Jul-01-19 07:30AM  ActoBio Therapeutics Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes PR Newswire
Jun-26-19 07:30AM  Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS) PR Newswire
Jun-25-19 08:32AM  Do Options Traders Know Something About Intrexon (XON) Stock We Don't? Zacks
Jun-19-19 09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks
Jun-18-19 03:46PM  Why Intrexon Stock Popped Today Motley Fool +13.16%
11:19AM  Intrexon Strikes $100M Partnership With Surterra For Cannabinoid Production Benzinga
09:05AM  Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production PR Newswire
Jun-13-19 07:30AM  Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference PR Newswire +7.66%
Jun-10-19 07:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares GuruFocus.com
11:59AM  Weekly CEO Buys Highlight GuruFocus.com
Jun-08-19 09:30AM  Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue? Zacks
Jun-04-19 07:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $998,306 of Shares GuruFocus.com
Jun-03-19 12:45PM  Weekly CEO Buys Highlight GuruFocus.com +6.61%
08:30AM  Oxitec Successfully Completes First Field Deployment of 2nd Generation Friendly Aedes aegypti Technology PR Newswire
07:30AM  Intrexon Announces Advances in Non-Browning GreenVenus Romaine Lettuce PR Newswire
06:43AM  Notable Insider Buys This Past Week: Coty, Zillow and More Benzinga
May-31-19 10:45AM  Intrexon CEO Made Big Open-Market Bets In May Benzinga
May-30-19 10:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.4 million of Shares GuruFocus.com
08:44AM  Fibrocell Up on FDA Designation for Gene Therapy Candidate Zacks
May-29-19 08:00AM  Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB GlobeNewswire
May-28-19 12:41PM  Weekly CEO Buys Highlight GuruFocus.com
07:30AM  Intrexon to Participate in 2019 BIO International Convention PR Newswire
May-24-19 09:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $1.9 million of Shares GuruFocus.com
May-21-19 11:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $2.9 million of Shares GuruFocus.com
11:41AM  Weekly CEO Buys Highlight GuruFocus.com
May-20-19 07:22PM  Cramer's lightning round: I feel bad if you own Intrexon It's a loser CNBC
02:55PM  Intrexon CEO buys up more company shares American City Business Journals
May-15-19 08:15PM  Intrexon Corp (XON) CEO Randal J Kirk Bought $5.5 million of Shares GuruFocus.com +6.29%
May-13-19 07:30AM  Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference PR Newswire
May-10-19 08:34AM  Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues Zacks
May-09-19 04:10PM  Intrexon Reports First Quarter 2019 Financial Results PR Newswire
May-02-19 04:30PM  AquaBounty Technologies, Inc. Announces Results for the Quarter Ended March 31, 2019, and Company Update GlobeNewswire
04:05PM  Intrexon to Release First Quarter 2019 Financial Results on May 9th PR Newswire
01:53PM  Heres What Hedge Funds Think Of Intrexon Corp (XON) Insider Monkey
10:32AM  Analysts Estimate Intrexon (XON) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-29-19 07:30AM  Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting PR Newswire
Apr-25-19 04:05PM  Precigen Opens Gene and Cell Therapy Manufacturing Facility in Germantown, Maryland PR Newswire
Apr-17-19 04:45PM  AquaBounty Technologies, Inc. Announces Exercise of Option to Purchase Additional Shares GlobeNewswire -12.43%
Apr-16-19 10:59AM  Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises Zacks +6.51%
07:30AM  Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper PR Newswire
Apr-15-19 06:30AM  Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy GlobeNewswire
Apr-10-19 07:30AM  Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference PR Newswire
Apr-09-19 04:00PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire -5.94%
07:30AM  Oxitec Advances Self-Limiting Fall Armyworm Control Solution to Next Phase of Development PR Newswire
Apr-08-19 08:28AM  Why Intrexon Stock Dropped 34% in March Motley Fool
Apr-04-19 09:55PM  AquaBounty Technologies, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock GlobeNewswire
04:08PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-03-19 07:30AM  Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management PR Newswire
Apr-02-19 07:00AM  AquaBounty Technologies, Inc. Environment and Climate Change Canada Approves Rollo Bay Facility for Commercial Production of AquAdvantage Salmon GlobeNewswire
Mar-30-19 09:30AM  Why Is Intrexon (XON) Down 34% Since Last Earnings Report? Zacks
Mar-22-19 04:00AM  Next Green Wave's Nursery Botticelli(TM) Research & Development Program Begins Newsfile -6.77%
Mar-21-19 04:01PM  AquaBounty Technologies, Inc. Announces Closing of Public Offering of Common Stock GlobeNewswire +5.69%
Mar-19-19 06:00AM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-18-19 04:00PM  AquaBounty Technologies, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-12-19 07:20AM  Jim Cramer Shares His Thoughts On Ambarella, Centurylink, Chipotle And More Benzinga
Mar-08-19 03:19PM  AquaBounty Technologies, Inc. - FDA Lifts Import Alert on AquAdvantage Salmon GlobeNewswire
Mar-07-19 05:00PM  AquaBounty Technologies, Inc. Results for the year ended December 31, 2018 GlobeNewswire +9.11%
Mar-05-19 06:41PM  Edited Transcript of XON earnings conference call or presentation 28-Feb-19 10:30pm GMT Thomson Reuters StreetEvents +21.26%
04:01PM  Here's What Caused Intrexon's 21% Rally Today Motley Fool
07:45AM  Market Trends Toward New Normal in Ritchie Bros. Auctioneers, Empire State Realty Trust, Synergy Resources, IQVIA, Intrexon, and Denbury Resources Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Mar-04-19 04:47PM  Here's Why Intrexon Crashed (Again) Today Motley Fool -18.18%
04:03PM  Intrexon, Surterra Wellness Collaborate On Plant Propagation For Cannabis Cultivation Benzinga
07:30AM  Intrexon and Surterra Wellness to Collaborate on Botticelli Next Generation Plant Propagation for Cannabis Cultivation PR Newswire
Mar-01-19 09:16AM  Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4 Zacks -36.51%
01:40AM  Intrexon Corp (XON) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:15PM  Intrexon Reports 2018 Fourth Quarter and Year End Financial Results PR Newswire
Feb-27-19 07:30AM  Intrexon to Showcase Differentiated Methane Bioconversion Platform at Upcoming Petroleum Industry Events PR Newswire
Feb-21-19 07:30AM  Intrexon to Announce Fourth Quarter 2018 Financial Results on February 28th PR Newswire
Feb-20-19 09:00AM  Intrexon's Subsidiary Precigen to Present at the SVB Leerink 8th Annual Global Healthcare Conference PR Newswire
Feb-14-19 08:20AM  Consolidated Research: 2019 Summary Expectations for Sabre, Groupon, Intrexon, Comfort Systems, O'Reilly Automotive, and Ellington Financial Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-11-19 07:30AM  Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients PR Newswire
Jan-25-19 09:44AM  Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks
Jan-21-19 09:21AM  Can This Stock Go From Potential Zika Virus Savior to Marijuana Kingpin? Motley Fool
Jan-16-19 04:19PM  Intrexon Signs Licensing Agreement with Next Green Wave Zacks
Jan-15-19 11:22AM  RETRANSMISSION: Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile
07:30AM  Next Green Wave Signs Licensing Agreement with Global Biotech Leader Intrexon Newsfile
07:30AM  Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli Next Generation Plant Propagation Platform into Development for Cannabis PR Newswire
Jan-08-19 08:00AM  Investing in a New Age of Cannabinoid Production for Cost Efficiency and Scalability GlobeNewswire
Jan-02-19 07:30AM  Intrexon Announces Presentations at Upcoming Investor Conferences PR Newswire +9.33%
Dec-31-18 07:30AM  Precigen to Debut Portfolio at Investor Event during the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-24-18 07:30AM  Precigen to Host Conference Call to Provide Business Updates PR Newswire
Dec-21-18 12:35PM  Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndrome (MDS) PR Newswire
07:30AM  Exemplar Genetics and Mayo Clinic Launch Joint Venture Focused on Development of Human Liver Cells to Advance Medical Research PR Newswire
Dec-20-18 03:23PM  AquaBounty Technologies, Inc.: Issuance of USDA labeling rule GlobeNewswire
07:42AM  Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon PR Newswire
Intrexon Corporation engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Intrexon Corporation has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Genomatix Ltd. and changed its name to Intrexon Corporation in 2005. Intrexon Corporation was founded in 1998 and is based in Germantown, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Perez Jeffrey ThomasSVP, IP AffairsOct 01Sale5.504,52124,84752,365Oct 02 05:25 PM
Bostick ThomasChief Operating OfficerOct 01Sale5.504,52124,84745,697Oct 02 05:25 PM
Sabzevari HelenPresident, Precigen, Inc.Oct 01Sale5.505,00527,50771,677Oct 02 05:25 PM
Sterling Rick L.Chief Financial OfficerOct 01Sale5.504,52124,847114,449Oct 02 05:25 PM
Reed Thomas D.Chief Science OfficerOct 01Sale5.503,65820,104117,777Oct 02 05:25 PM
Lehr Donald P.Chief Legal OfficerOct 01Sale5.505,00127,48566,816Oct 02 05:24 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 18Sale7.478,48463,37762,341Jul 19 05:21 PM
Walsh Robert F. IIISVP, Energy & Fine Chem.Jul 01Sale7.765,00738,85428,816Jul 02 07:13 PM
Sabzevari HelenPresident, Precigen, Inc.Jul 01Sale7.764,82237,41945,825Jul 02 07:12 PM
Sterling Rick L.Chief Financial OfficerJul 01Sale7.764,35933,826104,629Jul 02 07:13 PM
Perez Jeffrey ThomasSVP, IP AffairsJul 01Sale7.764,35933,82642,545Jul 02 07:11 PM
Reed Thomas D.Chief Science OfficerJul 01Sale7.763,52727,370107,094Jul 02 07:12 PM
Bostick ThomasChief Operating OfficerJul 01Sale7.764,35933,82635,877Jul 02 07:10 PM
Lehr Donald P.Chief Legal OfficerJul 01Sale7.764,82237,41957,476Jul 02 07:11 PM
KIRK RANDAL JChief Executive OfficerJun 07Buy5.26222,3551,169,58718,268,451Jun 10 05:19 PM
KIRK RANDAL JChief Executive OfficerJun 07Buy5.26148,237779,7271,142,758Jun 10 05:20 PM
KIRK RANDAL JChief Executive OfficerJun 06Buy5.23173,942909,7171,113,111Jun 10 05:20 PM
KIRK RANDAL JChief Executive OfficerJun 06Buy5.23260,9131,364,57518,138,648Jun 10 05:19 PM
KIRK RANDAL JChief Executive OfficerJun 04Buy5.1745,120233,2701,078,323Jun 04 06:05 PM
KIRK RANDAL JChief Executive OfficerJun 04Buy5.1767,679349,90017,986,337Jun 04 06:01 PM
KIRK RANDAL JChief Executive OfficerMay 31Buy4.78135,642648,36917,902,546Jun 04 06:01 PM
KIRK RANDAL JChief Executive OfficerMay 31Buy4.7890,428432,2461,069,299Jun 04 06:05 PM
KIRK RANDAL JChief Executive OfficerMay 30Buy4.79307,5921,473,36617,823,362May 30 07:42 PM
KIRK RANDAL JChief Executive OfficerMay 30Buy4.79205,060982,2371,051,213May 30 07:47 PM
KIRK RANDAL JChief Executive OfficerMay 29Buy4.68125,120585,5621,010,201May 30 07:47 PM
KIRK RANDAL JChief Executive OfficerMay 29Buy4.68187,679878,33817,643,801May 30 07:42 PM
KIRK RANDAL JChief Executive OfficerMay 24Buy4.6872,430338,972985,177May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 24Buy4.68108,645508,45917,534,241May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.67128,626600,68317,470,818May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 23Buy4.6785,750400,453970,691May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70115,187541,379953,541May 24 07:29 PM
KIRK RANDAL JChief Executive OfficerMay 22Buy4.70172,779812,06117,395,730May 24 07:23 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7460,223285,457930,504May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 21Buy4.7490,335428,18817,294,866May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63452,5022,095,08417,242,131May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 20Buy4.63301,6701,396,732918,459May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6960,530283,886858,125May 21 08:07 PM
KIRK RANDAL JChief Executive OfficerMay 17Buy4.6990,794425,82416,977,975May 21 08:05 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59471,0772,162,24316,924,973May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 15Buy4.59314,0501,441,490846,019May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37147,500644,575783,209May 15 05:38 PM
KIRK RANDAL JChief Executive OfficerMay 14Buy4.37221,251966,86716,649,972May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25565,3992,402,94616,520,814May 15 05:36 PM
KIRK RANDAL JChief Executive OfficerMay 13Buy4.25376,9321,601,961753,709May 15 05:38 PM
KIRK RANDAL J10% OwnerApr 03Sale0.6595,24161,90762,342Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 02Sale0.6613,6469,00688,422Apr 03 05:13 PM
KIRK RANDAL J10% OwnerApr 01Sale0.6741,67827,92492,159Apr 03 05:13 PM
MITCHELL DEAN JDirectorMar 12Option Exercise3.178,90628,23241,750Mar 12 07:11 PM
Reed Thomas D.Chief Science OfficerMar 05Sale4.662,30010,71841,705Mar 06 09:07 PM
Reed Thomas D.Chief Science OfficerMar 04Sale4.18225,500943,69044,005Mar 06 09:07 PM
ALVAREZ CESAR LDirectorFeb 19Option Exercise3.172,9689,409117,817Feb 21 04:46 PM
Frank StevenDirectorFeb 12Option Exercise3.172,9689,409195,225Feb 14 04:41 PM
Reed Thomas D.Chief Science OfficerFeb 07Option Exercise3.172,9699,41296,280Feb 11 04:57 PM
LIFFMAN JOEL DSVP, FinanceJan 04Sale7.033,72526,18785,541Jan 04 06:46 PM
Walsh Robert F. IIISVP, Energy & Fine Chem.Jan 03Sale7.074,05828,6925,708Jan 04 06:46 PM
Reed Thomas D.Chief Science OfficerJan 03Sale7.072,94420,81679,537Jan 04 06:47 PM
Perez Jeffrey ThomasSVP, IP AffairsJan 03Sale7.073,51424,84618,789Jan 04 06:48 PM
Lehr Donald P.Chief Legal OfficerJan 03Sale7.073,83227,09434,183Jan 04 06:48 PM
Sterling Rick L.Chief Financial OfficerJan 03Sale7.073,51424,84680,873Jan 04 06:46 PM
Sabzevari HelenPresident, Precigen, Inc.Jan 03Sale7.073,83227,09422,532Jan 04 06:46 PM
Nimrodi NirChief Business OfficerJan 03Sale7.074,05828,6925,708Jan 04 06:45 PM
Reed Thomas D.Chief Science OfficerDec 31Sale6.3630,000190,67172,715Jan 03 05:56 PM
open in yahoo | open in reuters | open in google